Merck and Eisai Provide Update on Phase 3 Trials of KEYTRUDA® Plus LENVIMA® In Certain Patients With Advanced Melanoma and Metastatic Colorectal Cancer Pharmaceutical Investing
MRNA-4157/V940, an Investigational Personalized MRNA Cancer Vaccine, in Combination With Keytruda , Receives Prime Scheme Designation From the European Medicines Agency for Adjuvant Treatment of Patients With High-Risk Stage III/IV Melanoma Following Complete Resection Pharmaceutical Investing
BELLUS Health Announces Positive Results from its Phase 1 Bioavailability Equivalence Study Evaluating Once-Daily Extended-Release Formulation of Camlipixant in Comparison to Twice-Daily Immediate Release Formulation Pharmaceutical Investing
Aurinia Pharmaceuticals Announces Promising Topline Data from Renal Biopsy Sub-study of the AURORA Trial Pharmaceutical Investing
Johnson & Johnson Subsidiary LTL Management LLC Re-Files for Voluntary Chapter 11 to Equitably Resolve All Current and Future Talc Claims Pharmaceutical Investing
Merck Ranked No. 1 in the Pharmaceutical Industry Among Barron's 100 Most Sustainable U.S. Companies 2023 Life Science Investing News
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Univar Solutions Inc. , Oak Street Health , Seagen Inc. , U.S. Xpress Enterprises, Inc. Pharmaceutical Investing
Lobe Sciences to Present at Sequire Cannabis & Psychedelics Conference April 5, 2023 Pharmaceutical Investing
